Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)

Mitsumi Terada; Hiroki Hara; Hiroyuki Daiko; Junki Mizusawa; Tomohiro Kadota; Keisuke Hori; Hirofumi Ogawa; Takashi Ogata; Katsuyuki Sakanaka; Takeshi Sakamoto; Ken Kato; Yuko Kitagawa

doi:10.1093/jjco/hyz112

Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)

Mitsumi Terada, Hiroki Hara, Hiroyuki Daiko, Junki Mizusawa, Tomohiro Kadota, Keisuke Hori, Hirofumi Ogawa, Takashi Ogata, Katsuyuki Sakanaka, Takeshi Sakamoto, Ken Kato, Yuko Kitagawa

Vice-President

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

A randomized phase III trial commenced in Japan in February 2018. Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced unresectable esophageal carcinoma. The purpose of this study is to confirm the superiority of induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery or definitive CRT over definitive CRT alone for overall survival (OS) in patients with locally advanced unresectable squamous-cell carcinoma of thoracic esophagus. A total of 230 patients will be accrued from 47 Japanese institutions over 4.5 years. The primary endpoint is OS, and the secondary endpoints are progression-free survival, complete response rate of CRT, response rate of DCF, adverse events of DCF and CRT, late adverse events and surgical complications. This trial has been registered at the Japan Registry of Clinical Trials as jRCTs031180181.

Original language	English
Pages (from-to)	1055-1060
Number of pages	6
Journal	Japanese journal of clinical oncology
Volume	49
Issue number	11
DOIs	https://doi.org/10.1093/jjco/hyz112
Publication status	Published - 2019 Nov 1

Keywords

esophageal neoplasms
induction chemotherapy
salvage therapy

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jjco/hyz112

Fingerprint

Dive into the research topics of 'Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)'. Together they form a unique fingerprint.

Cite this

Terada, M., Hara, H., Daiko, H., Mizusawa, J., Kadota, T., Hori, K., Ogawa, H., Ogata, T., Sakanaka, K., Sakamoto, T., Kato, K., & Kitagawa, Y. (2019). Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Japanese journal of clinical oncology, 49(11), 1055-1060. https://doi.org/10.1093/jjco/hyz112

Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). / Terada, Mitsumi; Hara, Hiroki; Daiko, Hiroyuki et al.
In: Japanese journal of clinical oncology, Vol. 49, No. 11, 01.11.2019, p. 1055-1060.

Research output: Contribution to journal › Article › peer-review

Terada, M, Hara, H, Daiko, H, Mizusawa, J, Kadota, T, Hori, K, Ogawa, H, Ogata, T, Sakanaka, K, Sakamoto, T, Kato, K & Kitagawa, Y 2019, 'Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)', Japanese journal of clinical oncology, vol. 49, no. 11, pp. 1055-1060. https://doi.org/10.1093/jjco/hyz112

Terada M, Hara H, Daiko H, Mizusawa J, Kadota T, Hori K et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Japanese journal of clinical oncology. 2019 Nov 1;49(11):1055-1060. doi: 10.1093/jjco/hyz112

Terada, Mitsumi ; Hara, Hiroki ; Daiko, Hiroyuki et al. / Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510 : TRIANgLE). In: Japanese journal of clinical oncology. 2019 ; Vol. 49, No. 11. pp. 1055-1060.

@article{8c5467b09e3149aab055457c927c5121,

title = "Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)",

abstract = "A randomized phase III trial commenced in Japan in February 2018. Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced unresectable esophageal carcinoma. The purpose of this study is to confirm the superiority of induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery or definitive CRT over definitive CRT alone for overall survival (OS) in patients with locally advanced unresectable squamous-cell carcinoma of thoracic esophagus. A total of 230 patients will be accrued from 47 Japanese institutions over 4.5 years. The primary endpoint is OS, and the secondary endpoints are progression-free survival, complete response rate of CRT, response rate of DCF, adverse events of DCF and CRT, late adverse events and surgical complications. This trial has been registered at the Japan Registry of Clinical Trials as jRCTs031180181.",

keywords = "esophageal neoplasms, induction chemotherapy, salvage therapy",

author = "Mitsumi Terada and Hiroki Hara and Hiroyuki Daiko and Junki Mizusawa and Tomohiro Kadota and Keisuke Hori and Hirofumi Ogawa and Takashi Ogata and Katsuyuki Sakanaka and Takeshi Sakamoto and Ken Kato and Yuko Kitagawa",

note = "Funding Information: This study is supported by the National Cancer Center Research and Development Fund (29-A-3) and Japan Agency for Medical Research and Development (AMED) under the Grant Number JP18ck0106431. Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press. All rights reserved.",

year = "2019",

month = nov,

day = "1",

doi = "10.1093/jjco/hyz112",

language = "English",

volume = "49",

pages = "1055--1060",

journal = "Japanese journal of clinical oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510

T2 - TRIANgLE)

AU - Terada, Mitsumi

AU - Hara, Hiroki

AU - Daiko, Hiroyuki

AU - Mizusawa, Junki

AU - Kadota, Tomohiro

AU - Hori, Keisuke

AU - Ogawa, Hirofumi

AU - Ogata, Takashi

AU - Sakanaka, Katsuyuki

AU - Sakamoto, Takeshi

AU - Kato, Ken

AU - Kitagawa, Yuko

N1 - Funding Information: This study is supported by the National Cancer Center Research and Development Fund (29-A-3) and Japan Agency for Medical Research and Development (AMED) under the Grant Number JP18ck0106431. Publisher Copyright: © 2019 The Author(s) 2019. Published by Oxford University Press. All rights reserved.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - A randomized phase III trial commenced in Japan in February 2018. Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced unresectable esophageal carcinoma. The purpose of this study is to confirm the superiority of induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery or definitive CRT over definitive CRT alone for overall survival (OS) in patients with locally advanced unresectable squamous-cell carcinoma of thoracic esophagus. A total of 230 patients will be accrued from 47 Japanese institutions over 4.5 years. The primary endpoint is OS, and the secondary endpoints are progression-free survival, complete response rate of CRT, response rate of DCF, adverse events of DCF and CRT, late adverse events and surgical complications. This trial has been registered at the Japan Registry of Clinical Trials as jRCTs031180181.

AB - A randomized phase III trial commenced in Japan in February 2018. Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced unresectable esophageal carcinoma. The purpose of this study is to confirm the superiority of induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery or definitive CRT over definitive CRT alone for overall survival (OS) in patients with locally advanced unresectable squamous-cell carcinoma of thoracic esophagus. A total of 230 patients will be accrued from 47 Japanese institutions over 4.5 years. The primary endpoint is OS, and the secondary endpoints are progression-free survival, complete response rate of CRT, response rate of DCF, adverse events of DCF and CRT, late adverse events and surgical complications. This trial has been registered at the Japan Registry of Clinical Trials as jRCTs031180181.

KW - esophageal neoplasms

KW - induction chemotherapy

KW - salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=85073918624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073918624&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyz112

DO - 10.1093/jjco/hyz112

M3 - Article

C2 - 31411696

AN - SCOPUS:85073918624

SN - 0368-2811

VL - 49

SP - 1055

EP - 1060

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

IS - 11

ER -

Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this